Table 2.

Difference (_ΔHLA-G) with mAbs 4H84 and 5A6G7 related to the clinical parameters in CRC patients.

Variables	Cases	ΔHLA-G*				HLA-G (mAb 4H84 vs. 5A6G7)
		Neg.	Com	Pos	p**	Cases	4H84neg 5A6G7pos	4H84pos 5A6G7neg	p**
Total	379	64	159	156		137	44	93
Gender
Male	214	35	96	83	0.418	76	25	51	0.828
Female	165	29	63	73		61	19	42
Age
≤ median (66 ys)	188	32	79	77	0.996	68	21	47	0.759
>median	191	32	80	79		69	23	46
TNM stage
Tumor status
T1+2	108	19	47	42	0.821	33	10	23	0.175
T3	256	41	107	108		100	31	69
T4	15	4	5	6		4	3	1
Nodal status
N0	201	33	88	80	0.634	65	20	45	0.356
N1	109	22	40	47		46	18	28
N2	69	9	31	29		26	6	20
Metastasis
M0	368	63	154	151	0.782	134	44	90	0.228
M1	11	1	5	5		3	0	3
Disease stage
I	85	14	41	30	0.885	23	9	14	0.417
II	114	19	47	48		42	11	31
III	169	30	66	73		69	24	45
IV	11	1	5	5		3	0	3

^*_ΔHLA-G: the difference of the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. _ΔHLA-G_neg:ΔHLA-G >−5.0%; _ΔHLA-G_com:−5.0%≤_ΔHLA-G≤5.0%; _ΔHLA-G_pos: _ΔHLA-G > 5.0%.

^**Comparison of HLA-G expression status between or among each variable using the Pearson chi-square test. TNM, lymph-node-metastasis and stage according to the TNM classification.